Adding radium-223 to treatment with enzalutamide and a bone-protecting agent improved rPFS and OS in patients with mCRPC and ...

自进入临床以来，Ra-223积累了丰富的循证证据。整体而言，其临床应用是逐渐由后线治疗向早期治疗迈进，并在联合治疗策略中展现出令人振奋的疗效潜力。本次ESMO公布的RAPSON研究结果为早期启动Ra-223提供了新的证据，更重要的是为患者提供了更佳的 ...

Adding radium-223 to enzalutamide significantly improved survival outcomes in patients with metastatic castration-resistant prostate cancer and bone metastases. Combining radium-223 (Xofigo) with ...

The RAPSON trial found that receiving radium-223 prior to docetaxel in patients with metastatic castration-resistant prostate ...

The addition of radium-223 to enzalutamide led to significant rPFS and OS benefits compared to enzalutamide alone in metastatic castration-resistant prostate cancer. Adding radium-223 (Xofigo) to ...

Combining radium-223 with enzalutamide offered a survival benefit in metastatic castration-resistant prostate cancer, but experts questioned its relevance in a shifting treatment landscape.

Men with castration-resistant prostate cancer (CRPC) and asymptomatic or mildly symptomatic bone metastases lived ...